Skip to content

Influence of Clonidine on Thrombozytes of Blood of Patients Under Anticoagulation Therapy With ASS and Clopidogrel

The Influence of Clonidine on the Thrombozytes of Patients Under Double Anticagulation With ASS and Clopidogrel - an in Vitro Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01314235
Enrollment
Unknown
Registered
2011-03-14
Start date
2010-10-31
Completion date
Unknown
Last updated
2011-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulation

Keywords

anticoagulation with ASS, anticoagulation with clopidogrel

Brief summary

Clonidin works as a presynaptic agonist of alpha-sympathomimetic receptors of the brain but also in many other tissues. It is part of balanced anesthesia in general anesthesiology as well as a sedastive agent in intensive care units, but also serves as a third-line agent in many psychiatric diseases including ADHD, schizophrenia and PTSD. The investigators want to show whether clonidin has an procoagulatoric effect on thrombozytes of patients under double anticoagulaotirc treatment with ASS and clopidogrel. The investigators will use a flowcytometric assay to determine activation of thrombozytes when they come into contact with clonidine in vitro as well as Multiplate analyses to determine activation of thrombozytes, either thrombin.induced aggregation, ADP-induced aggregation or arachidonic acid-induced aggregation of thrombozytes.

Interventions

None listed

Sponsors

Goethe University
Lead SponsorOTHER

Study design

Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Elective vascular surgical patients with long-term medication (at least 5 days) with ASS and clopidogrel * Age above 18 years

Exclusion criteria

* Additional anticoagulatoric treatment woth another inhibitor of platelet aggregation * Surgery within the last two weeks * Patients with long-term mediaction with omeprazole * Patients under hemodialysis * Patients with renal insufficiency (creatinine above 1.5mg/dl, urea above 80mg/dl) * Patients with hepatic dysfunction (GOT above 30U/I, GPT above 30 U/I, GLDH above 10 U/I) * Age under 18 yeary * Non-responder to ASS and / or clopidogrel

Design outcomes

Primary

MeasureTime frameDescription
Numbers of participants with an activated area under the curve in ASPI test30 minutesBlood of patients under ASS and clopidogrel will show an activated platelet aggregation due to titrated clonidine in ASPI test, i.e. an activated area under the curve in Multiplate analysis.

Secondary

MeasureTime frameDescription
Numbers of participants with an activated area under the curve in TRAP test and ADP test30 minutesBlood of patients under ASS and clopidogrel will show an activated platelet aggregation due to titrated clonidine in TRAP test and ADP test, i.e. an activated area under the curve in Multiplate analysis.

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026